Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intensive Case Management for Substance Use Disorders (RCT) (ICM)

13 november 2026 bijgewerkt door: Psychiatric Services Aargau AG

Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial

This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.

Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).

Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.

In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:

  • People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
  • people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
  • patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
  • people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.

Sex and gender will be treated as potential covariates and will be considered in the analysis.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

180

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Canton of Aargau
      • Windisch, Canton of Aargau, Zwitserland, 5210
        • Werving
        • PDAG
        • Contact:
        • Hoofdonderzoeker:
          • Johannes Senesi, Msc

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 64 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • 4 or more inpatient admissions in the last 24 months
  • Diangosed SUD
  • Residence or temporary stay in the canton of Aargau

Exclusion Criteria:

  • any emergency situation requiring psychiatric or hospital admissions
  • inability to give informed consent
  • acute, unstable psychotic symptoms
  • acute risk of harm to self or others
  • insufficient german language skills

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Experimental

receives ICM immediately

Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:

  1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients.
  2. Relationship continuity: Establishing an empathetic & constant presence, breaking down barriers, creating a trustful, stable relationship.
Actieve vergelijker: Waiting List

Same as Experimental, only with 6-Month TAU-Waiting List before ICM

TAU will take place for 6 months before starting with ICM

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Inpatient Admissions (Health Service utilisation)
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Number of Inpatient Days (Health Service utilisation)
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
WHOQoL-BREF
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Quality of Life

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
SFQ
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Social Functioning Questionnaire

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
ASSIST
Tijdsspanne: 6 Months (exploratory), 24 months (exploratory)

Substance use characteristics

6 Months (exploratory), 24 months (exploratory)
Continuity of Care (Brice-Boxerman)
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Continuity of Care describes timeframes of the health services used outside the ward.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Linking
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Retention
Tijdsspanne: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Retention describes the voluntary staying of patients in the ICM treatment

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
BSCL
Tijdsspanne: 6 Months (exploratory), 24 months (exploratory)

Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care

6 Months (exploratory), 24 months (exploratory)
EQ-5D-5L
Tijdsspanne: 6 Months (exploratory), 24 months (exploratory)

EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)

6 Months (exploratory), 24 months (exploratory)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

4 juli 2026

Primaire voltooiing (Geschat)

1 juli 2029

Studie voltooiing (Geschat)

1 juli 2029

Studieregistratiedata

Eerst ingediend

13 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • PDAG-ICM
  • HumRes68440 (Andere identificatie: Human Research Switzerland (HumRes))

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren